Company profile for InflammX Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

InflammX Therapeutics focuses on novel treatments targeting the dysregulated inflammasome (NLRP3) pathway in autoinflammatory diseases. Their lead product, Xiflam™, is a once-daily oral small molecule targeting Connexin43 (Cx43) Hemichannel to inhibit inflammasome activation. Xiflam™ is currently in clinical development for Diabetic Macular Edema (DME), Diabetic Chronic Kidney Disease (CKD), and intermediate-stage Macular ...
InflammX Therapeutics focuses on novel treatments targeting the dysregulated inflammasome (NLRP3) pathway in autoinflammatory diseases. Their lead product, Xiflam™, is a once-daily oral small molecule targeting Connexin43 (Cx43) Hemichannel to inhibit inflammasome activation. Xiflam™ is currently in clinical development for Diabetic Macular Edema (DME), Diabetic Chronic Kidney Disease (CKD), and intermediate-stage Macular Degeneration (iAMD).

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
275 Bayshore Blvd, Unit 1607 Tampa, FL, 33606
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty